Experts preview promising triple-negative breast cancer studies for ASCO 2026

At the 2026 ASCO Annual Meeting, leading breast cancer specialists highlighted the triple-negative breast cancer (TNBC) abstracts they consider most likely to influence clinical practice.

The discussion featured VK Gadi of the University of Illinois, Erika Hamilton from Sarah Cannon Research Institute, Kevin Kalinsky of Emory University, and Alexis LeVee of UCLA Health. Each expert pointed to specific upcoming datasets, including novel biomarker analyses and early‑stage combination therapy trials.

They expect that the forthcoming data could shape treatment decisions for patients with TNBC, offering new options and informing future research directions.